These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 30975913)
41. Identification of AML1-ETO modulators by chemical genomics. Corsello SM; Roti G; Ross KN; Chow KT; Galinsky I; DeAngelo DJ; Stone RM; Kung AL; Golub TR; Stegmaier K Blood; 2009 Jun; 113(24):6193-205. PubMed ID: 19377049 [TBL] [Abstract][Full Text] [Related]
42. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia. Kuchenbauer F; Feuring-Buske M; Buske C Cell Cycle; 2005 Dec; 4(12):1716-8. PubMed ID: 16294039 [TBL] [Abstract][Full Text] [Related]
43. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Yan M; Ahn EY; Hiebert SW; Zhang DE Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704 [TBL] [Abstract][Full Text] [Related]
44. Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes. Mitkevich VA; Petrushanko IY; Spirin PV; Fedorova TV; Kretova OV; Tchurikov NA; Prassolov VS; Ilinskaya ON; Makarov AA Cell Cycle; 2011 Dec; 10(23):4090-7. PubMed ID: 22101339 [TBL] [Abstract][Full Text] [Related]
45. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells. Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846 [TBL] [Abstract][Full Text] [Related]
46. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Fenske TS; Pengue G; Mathews V; Hanson PT; Hamm SE; Riaz N; Graubert TA Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15184-9. PubMed ID: 15477599 [TBL] [Abstract][Full Text] [Related]
47. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Elagib KE; Goldfarb AN Cancer Lett; 2007 Jun; 251(2):179-86. PubMed ID: 17125917 [TBL] [Abstract][Full Text] [Related]
49. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development. DeKelver RC; Lewin B; Weng S; Yan M; Biggs J; Zhang DE Leuk Lymphoma; 2014 Apr; 55(4):884-91. PubMed ID: 23772668 [TBL] [Abstract][Full Text] [Related]
50. AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation. Bäsecke J; Schwieger M; Griesinger F; Schiedlmeier B; Wulf G; Trümper L; Stocking C Leuk Lymphoma; 2005 Feb; 46(2):265-72. PubMed ID: 15621811 [TBL] [Abstract][Full Text] [Related]
51. Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis. Lu Y; Xu YB; Yuan TT; Song MG; Lübbert M; Fliegauf M; Chen GQ Leukemia; 2006 Jun; 20(6):987-93. PubMed ID: 16598301 [TBL] [Abstract][Full Text] [Related]
52. The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells. Yan JS; Li YD; Liu SH; Yin QQ; Liu XY; Xia L; Lu Y Leuk Lymphoma; 2017 Aug; 58(8):1985-1988. PubMed ID: 28092997 [No Abstract] [Full Text] [Related]
53. Comparative proteomic analysis of human leukemic cells with and without inducible expression of leukemogenic AML1-ETO protein. Zhang L; Wang LS; Xu Y; Xia L; Chen WL; Zheng Y; Chen GQ Chin J Physiol; 2006 Aug; 49(4):182-91. PubMed ID: 17058450 [TBL] [Abstract][Full Text] [Related]
54. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells. Li X; Xu YB; Wang Q; Lu Y; Zheng Y; Wang YC; Lübbert M; Zhao KW; Chen GQ J Cell Physiol; 2006 Sep; 208(3):594-601. PubMed ID: 16741927 [TBL] [Abstract][Full Text] [Related]
55. Genetic manipulation of AML1-ETO-induced expansion of hematopoietic precursors in a Drosophila model. Sinenko SA; Hung T; Moroz T; Tran QM; Sidhu S; Cheney MD; Speck NA; Banerjee U Blood; 2010 Nov; 116(22):4612-20. PubMed ID: 20688956 [TBL] [Abstract][Full Text] [Related]
56. AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. Steffen B; Knop M; Bergholz U; Vakhrusheva O; Rode M; Köhler G; Henrichs MP; Bulk E; Hehn S; Stehling M; Dugas M; Bäumer N; Tschanter P; Brandts C; Koschmieder S; Berdel WE; Serve H; Stocking C; Müller-Tidow C Blood; 2011 Apr; 117(16):4328-37. PubMed ID: 21245488 [TBL] [Abstract][Full Text] [Related]
57. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Peterson LF; Yan M; Zhang DE Blood; 2007 May; 109(10):4392-8. PubMed ID: 17284535 [TBL] [Abstract][Full Text] [Related]
58. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Shia WJ; Okumura AJ; Yan M; Sarkeshik A; Lo MC; Matsuura S; Komeno Y; Zhao X; Nimer SD; Yates JR; Zhang DE Blood; 2012 May; 119(21):4953-62. PubMed ID: 22498736 [TBL] [Abstract][Full Text] [Related]
59. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Yan M; Burel SA; Peterson LF; Kanbe E; Iwasaki H; Boyapati A; Hines R; Akashi K; Zhang DE Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17186-91. PubMed ID: 15569932 [TBL] [Abstract][Full Text] [Related]